BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
Scott Buck, an analyst from H.C. Wainwright, reiterated the Buy rating on SoundHound AI, Inc Class A (SOUN – Research Report). The ...
Hosted on MSN1d
5 Semiconductor Stocks to Buy Now for More Upside in 2025The artificial intelligence (AI) megatrend has surged across markets over the last two years, generating substantial wealth ...
Nvidia stock has been the poster child for artificial intelligence and continues to defy the odds. But is the stock still a ...
BP p.l.c.'s recent management changes and strategic moves, including the Travel Centers of America acquisition, signal a ...
Hosted on MSN1d
Datadog (DDOG) Upgraded to Buy: Here's What You Should KnowDatadog (DDOG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...
Bank of America has a "buy" rating and $240 price target for JPM stock, which closed at $236.98 on Nov. 8. Home Depot is one of the largest North American home improvement retailers. Analyst ...
MTU Aero Engines is poised for long-term growth with strong revenues, earnings, and stock performance, making it a buy with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback